Designing allosteric activators of CSE as novel oral inhibitors of pathologic calcification

• Unité de recherche: INNOSUISSE
• Numéro de projet: 124.461 IP-LS
• Titre du projet anglais: Designing allosteric activators of CSE as novel oral inhibitors of pathologic calcification

Mots-clé (Anglais)

Life sciences, Pharmaceuticals

Résumé des résultats (Abstract) (Anglais)

SULFISCON is developing small molecule activators of the enzyme CSE to modulate endogenous H2S production as a drug. We seek support to optimise pharmacologic properties of current lead compounds for oral administration and test their effects in animal models of pathologic calcification.